GALAPAGOS - Santa Arrives – Late but With Bounty!
Today’s exclusive global agreement of Galapagos’ (GLPG) GLPG0634 (PhII, RA, oral JAK1 inhibitor) with a veteran player in the RA field, Abbott, indeed is a very good deal! With the success of Humira (L, 2011A sales: $7.9b, anti-TNF alpha, RA, plaque psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and Juvenile Idiopathic Arthritis), Abbott must have done its due diligence thoroughly to justify the deal value of $1.35b. If the data from the small study is replicated in larger trials, this drug has the potential to oust other JAK inhibitors. GLPG has several partnered and unpartnered programs besides a robust drug and novel target discovery platform. We expect it to aggressively push for... For more detail, please read our report released on 29th February on GLPG titled “Santa Arrives – Late but With Bounty!”
COMPANIES MENTIONED
GALAPAGOS
GALAPAGOS
